Lucitanib

Lucitanib
Clinical data
Other names	CO-3810, E-3810
Routes of; administration	By mouth
ATC code	None;
Legal status
Legal status	Investigational;
Pharmacokinetic data
Elimination half-life	31–40 hrs
Identifiers
	IUPAC name 6-({7-[(1-Aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl}oxy)-N-methyl-1-naphthamide;
CAS Number	1058137-23-7;
PubChem CID	25031915;
ChemSpider	28189586;
UNII	PP449XA4BH;
KEGG	D11762;
ChEBI	CHEBI:65209;
ChEMBL	ChEMBL2180605;
CompTox Dashboard (EPA)	DTXSID30147356 ;
Chemical and physical data
Formula	C26H25N3O4
Molar mass	443.503 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNC(=O)c1cccc2c1ccc(c2)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC;
	InChI InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30); Key:CUDVHEFYRIWYQD-UHFFFAOYSA-N;

Lucitanib (INN) is a drug that is being investigated by Clovis Oncology in clinical trials for the treatment of advanced solid tumours^[1] including metastatic breast cancer.^[2] It is a protein kinase inhibitor that blocks the VEGF receptors 1, 2 and 3, as well as the fibroblast growth factor receptors 1 and 2, and the platelet-derived growth factor receptors alpha and beta.^[1]

References

1 2 Soria JC, DeBraud F, Bahleda R, Adamo B, Andre F, Dienstmann R, et al. (November 2014). "Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors". Annals of Oncology. 25 (11): 2244–51. doi:10.1093/annonc/mdu390. PMID 25193991.
↑ Clinical trial number NCT02053636 for "A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer (FINESSE)" at ClinicalTrials.gov